• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

David F. McDermott, MD

Publications

  • Buchbinder EI, McDermott DF.Interferon, Interleukin-2, and Other Cytokines.Hematol Oncol Clin North Am. 2014 Jun;28(3):571-583.
    24880948
  • Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS.Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol. 2014 Apr 1;32(10):1020-30.
    24590637
  • Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ.Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.Cancer. 2014 Feb 27.
    24577748
  • Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK.The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.Eur Urol. 2014 Apr;65(4):723-30.
    24184025
  • Gunturi A, McDermott DF.Potential of new therapies like anti-PD1 in kidney cancer.Curr Treat Options Oncol. 2014 Mar;15(1):137-46.
    24504486
  • Flaherty L, Hamid O, Linette G, Schuchter L, Hallmeyer S, Gonzalez R, Cowey CL, Pavlick A, Kudrik F, Curti B, Lawson D, Chapman PB, Margolin K, Ribas A, McDermott D, Flaherty K, Cranmer L, Hodi FS, Day BM, Linke R, Hainsworth J.A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.Cancer J.;20(1):18-24.
    24445759
  • McDermott DF, Atkins MB.PD-1 as a potential target in cancer therapy.Cancer Med. 2013 Oct;2(5):662-73.
    24403232
  • Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, Stadler WM.FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.Cancer Med. 2013 Aug;2(4):545-52.
    24156027
  • Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS.A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.J Immunother.;36(9):490-5.
    24145360
  • Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB.The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.Nat Rev Clin Oncol. 2013 Oct;10(10):588-98.
    23982524
  • Mahoney KM, Ackerman A, Cho DC, McDermott DF, Peters T, Atkins MB.Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication.J Clin Oncol. 2013 Jul 20;31(21):e364-6.
    23752114
  • Bailey A, McDermott DF.Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics.Cancer J.;19(4):348-52.
    23867517
  • Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB.Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Br J Cancer. 2013 Apr 16;108(7):1393-401.
    23511559
  • Drakaki A, McDermott DF.Novel Immunotherapies in GU Malignancies.Curr Oncol Rep. 2013 Mar 22.
    23519772
  • Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.J Clin Oncol. 2013 Jan 10;31(2):181-6.
    23213094
  • Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK.Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.Lancet Oncol. 2013 Jan;14(1):81-7.
    23219378
  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med. 2012 Jun 28;366(26):2443-54.
    22658127
  • Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ.BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.J Clin Oncol. 2012 Jan 1;30(1):34-41.
    22124101
  • McDermott DF.Improving the therapeutic index of IL-2.Clin Adv Hematol Oncol. 2010 Dec;8(12):862-4.
    21326162
  • Pandya SS, Mier JW, McDermott DF, Cho DC.Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.BJU Int. 2011 Feb 14.
    21320274
  • Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK.Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Advanced Renal Cell Carcinoma.Eur Urol. 2011 Feb 1.
    21306819
  • Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF, Powles T, Chowdhury P, Karapetis C, Harper PG, Choueiri TK, Chowdhury S.Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.BJU Int. 2011 Jan 18.
    21244613
  • Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY.The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.J Urol. 2011 Jan;185(1):60-6.
    21074201
  • Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Cin PD, Corn P, Vaishampayan U, Heng DY, Tannir NM.Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.Cancer. 2010 Nov 15;116(22):5219-25.
    20665500
  • Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK.Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study☆.Urol Oncol. 2010 Oct 4.
    20926319
  • Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA.Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.Oncology. 2010;78(5-6):340-7.
    20733337
  • Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S.Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.BJU Int. 2010 Sep;106(6):772-8.
    20230385
  • Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R.Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.Med Oncol. 2010 Sep;27(3):899-906.
    19757215
  • Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med. 2010 Aug 19;363(8):711-23.
    20525992
  • Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY.Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy.Urology. 2010 Aug;76(2):430-4.
    20223508
  • McDermott DF, Ghebremichael M, Signoretti S, Margolin KA, Clark J, Sosman JA, Dutcher JP, French M, Regan MM, Atkins MB.The high-dose aldesleukin (HD IL-2) "Select" Trial in patients with metastatic renal cell carcinoma (mRCC).Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings.;28(15S):345s.
  • Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK.Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.BJU Int. 2010 May;105(9):1247-54.
    19863525
  • Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.Urol Oncol. 2010 May 5.
    20451414
  • McDermott DF, George DJ.Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data.Cancer Treat Rev. 2010 May;36(3):216-23. Review.
    20116176
  • Williams SB, McDermott DW, Winston D, Bahnson E, Berry AM, Steele GS, Richie JP.Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data.BJU Int. 2010 Apr;105(7):918-21.
    19747353
  • Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP.A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.Cancer. 2010 Apr 1;116(7):1751-6.
    20120033
  • Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, .Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.Cancer. 2010 Mar 1;116(5):1272-80.
    20082451
  • Gunturu KS, Meehan KR, Mackenzie TA, Crocenzi TS, McDermott D, Usherwood EJ, Margolin KA, Crosby NA, Atkins MB, Turk MJ, Ahonen C, Fuse S, Clark JI, Fisher JL, Noelle RJ, Ernstoff MS.Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.J Clin Oncol. 2010 Mar 1;28(7):1196-202.
    20124177
  • Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, Carberry M, Troxel AB, Letrero R, Nathanson KL, Atkins MB, O'Dwyer PJ, Flaherty KT.Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.Clin Cancer Res. 2009 Dec 15;15(24):7711-7718.
    19996224
  • Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK.Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.J Clin Oncol. 2009 Dec 1;27(34):5794-9.
    19826129
  • Clement JM, McDermott DF.The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.Clin Genitourin Cancer. 2009 Aug;7(2):E7-9. Review.
    19692326
  • Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G.Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.Cancer. 2009 Aug 15;115(16):3651-60.
    19526589
  • Demirjian AN, Vollmer CM, McDermott DF, Mullen JT, Atkins MB, Callery MP.Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreas.Hpb : The Official Journal Of The International Hepato Pancreato Biliary Association. 2009;11(2):150-3.
    19590640
  • Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G.Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.Med Oncol. 2009;26(2):202-9.
    19229667
  • Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L.Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.Cancer. 2009 May 15;115(10 Suppl):2247-51.
    19402064
  • Cho DC,Puzanov I,Regan MM,Schwarzberg T,Seery V,Lee MY,Liu V,Bhatt R,Koon H,Mier JW,Sosman JA,Atkins MB,McDermott DF.Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.J Immunother. 2009 Feb-Mar;32(2):181-5.
    19238017
  • Bylow KA,Atkins MB,Posadas EM,Stadler WM,McDermott DF.Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.Clin Genitourin Cancer. 2009 Jan;7(1):39-42.
    19213667
  • McDermott DF.The application of high-dose interleukin-2 for metastatic renal cell carcinoma.Med Oncol. 2009;26 Suppl 1:13-7. Review.
    19148594
  • McDermott DF,Atkins MB.Immunotherapy of metastatic renal cell carcinoma.Cancer J. 2008 Sep-Oct;14(5):320-4. Review.
    18836337
  • Libermann TA, Bhasin M, Joseph MG, Signoretti S, Ernstoff MS, McDermott D, Atkins MB.Gene Expression Profiling Signatures Associated with RCC response to IL-2 Therapy.Proceedings of the 23rd ISBTC Meeting, J Immunotherapy ..
  • Michaelson MD,Iliopoulos O,McDermott DF,McGovern FJ,Harisinghani MG,Oliva E.Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.N Engl J Med. 2008 May 29;358(22):2389-96.
    18509125
  • Regan MM, Brick AJ, Choueiri TK, Clement JM, Kwabi C, Shah K, Amato A, McDermott DF, Atkins MB, Signoretti S.Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy.J Clin Oncol..
  • Jaeger E, Waldman F, Roydasgupta R, Klatte T, McDermott DF, Signoretti S, Atkins MB, LaRochelle J, Belledegrun AS, Pantuck AJ.Array-based comparative genomic hybridization (CGH) identifies imbalances between interleukin-2 complete and non-responders.Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings.;26(15s):5043.
  • McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.J Clin Oncol. 2008 May 1;26(13):2178-85.
    18445842
  • Ernstoff M, Regan MM, McDermott DF, Sosman JA, Dutcher JP, Clark JI, Crocenzi TS, Ochoa A, Atkins MB.First Line therapy with bevacizumab (B) and high dose bolus (HD) aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) Patients (Pts).The Cytokine Working Group.ASCO Annual Meeting Proceedings. 2007;In Press.
  • Clark JI, Mehrabi J, Sosman JA, Logan TF, Margolin KA, Dutcher JP, Urba WJ, Ernstoff MS, McDermott DF, Lau AM, Atkins MB.Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.J Immunother. 2007 Nov-Dec;30(8):839-46.
    18049336
  • Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M.Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.Clin Genitourin Cancer. 2007 Sep;5(6):379-85.
    17956710
  • Chandrakantan A, McDermott DH, Tran HT, Jurewicz M, Gallon L, Gaston R, Milford E, Abdi R.Role of beta3 integrin in acute renal allograft rejection in humans.Clin J Am Soc Nephrol. 2007 Nov;2(6):1268-73.
    17928472
  • Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, Balding DJ, Chokkalingam A, Dolan SM, Flanders WD, Higgins JP, McCarthy MI, McDermott DH, Page GP, Rebbeck TR, Seminara D, Khoury MJ.Assessment of cumulative evidence on genetic associations: interim guidelines.Int J Epidemiol. 2008 Feb;37(1):120-32. Review.
    17898028
  • Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM.Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.J Immunother. 2007 Oct;30(7):749-61.
    17893567
  • Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D.Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.J Clin Oncol. 2007 Oct 10;25(29):4536-41.
    17876014
  • McDermott DF, Atkins MB.More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma.J Clin Oncol. 2007 Sep 1;25(25):3791-3.
    17761967
  • Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.J Clin Oncol. 2007 Sep 1;25(25):3958-64.
    17761980
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR.Phase I trial of parathyroid hormone to facilitate stem cell mobilization.Biol Blood Marrow Transplant. 2007 Jul;13(7):838-43.
    17580262
  • Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ,.Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.N Engl J Med. 2007 May 31;356(22):2271-81.
    17538086
  • McDermott DF, Rini BI.Immunotherapy for metastatic renal cell carcinoma.BJU Int. 2007 May;99(5 Pt B):1282-8. Review.
    17441925
  • McDermott DF.Update on the application of interleukin-2 in the treatment of renal cell carcinoma.Clin Cancer Res. 2007 Jan 15;13(2):716s-20s. Review.
    17255299
  • Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L.Innovations and challenges in renal cell carcinoma: summary statement from the second cambridge conference.Clin Cancer Res. 2007 Jan 15;13(2):667s-70s. Review.
    17255291
  • McDermott DF, Atkins MB.Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.Semin Oncol. 2006 Oct;33(5):583-7. Review.
    17045087
  • McDermott DF, Regan MM, Atkins MB.Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.Clin Genitourin Cancer. 2006 Sep;5(2):114-9. Review.
    17026799
  • Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA.Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.Cancer. 2006 May 1;106(9):2005-11.
    16565971
  • Cho D, McDermott D, Atkins M.Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools.Curr Urol Rep. 2006 Jan;7(1):8-15.
    16480663
  • Cho D, McDermott D, Atkins M.Designing Clinical Trials for Kidney Cancer Based on Newly Developed Prognostic and Predictive Tools.Current Urology Reports. 2006 JAN 01;7(1).
  • McDermott DF, Sosman J, Kirkwood J, Logan T, Gordon M, Flaherty L, Clark J, Weiss G, Margolin K, Ernstoff M, Urba W, Smith J, Parker R, Dutcher J, Atkins, M.A Randomized Phase II Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients with Metastatic Renal Carcinoma.J Clin Oncol.:In press.
  • Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB.Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.J Immunother. 2005 Sep-Oct;28(5):488-95.
    16113605
  • Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S.Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.Clin Cancer Res. 2005 May 15;11(10):3714-21.
    15897568
  • Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC.Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.Cancer Res. 2005 Apr 15;65(8):3044-8.
    15833831
  • McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB.Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.J Clin Oncol. 2005 Jan 1;23(1):133-41.
    15625368
  • Atkins MB, Regan M, McDermott D.Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6342S-6S.
    15448028
  • Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D.Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.Clin Cancer Res. 2004 Jul 15;10(14):4699-708.
    15269142
  • Carloss E, Regan M, Upton M, Youmans A, Polivy A, McDermott D, Atkins M.Concordance of local pathology interpretation with central pathology review in primary tumor specimens from patients with Renal Cancer (RCC).Journal of Clinical Oncology: ASCO. 2004 Jul 15;22(14 S):4548.
  • McDermott D, Parker R, Youmans A, Connolly C, Atkins MB.The Effect of Recent Nephrectomy on Treatment with High-dose Interleukin-2 (HD IL-2) or Subcutaneous (SC) IL-2/Interferon Alfa-2b (IFN) in Patients with Metastatic Renal Cell Carcinoma (RCC).Proceedings of the American Association of Clinical Oncology.;22:385 (abst 1547).
  • McDermott DF, Atkins MB.Application of IL-2 and other cytokines in renal cancer.Expert Opin Biol Ther. 2004 Apr;4(4):455-68.
    15102596
  • McDermott D, Parker R, Youmans A, Connolly C, Atkins MB.he Effect of Recent Nephrectomy on Treatment with High-dose Interleukin-2 (HD IL-2) or Subcutaneous (SC) IL-2/Interferon Alfa-2b (IFN) in Patients with Metastatic Renal Cell Carcinoma (RCC).Proceedings of the American Association of Clinical Oncology. 2003 Jul 01;22:387a.
  • Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB.Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.J Clin Oncol. 2003 Jul 1;21(13):2564-73.
    12829677
  • Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA.Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.J Clin Oncol. 2003 Aug 15;21(16):3133-40.
    12810695
  • Joyce RM, Regan M, Ottaway J, Umiel T, Tetreault JC, Levine J, McDermott D, Hurley D, Giallombardo N, Smith T, Lamontagne D, Uhl L, Avigan D.A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).Ann Oncol. 2003;14 Suppl 1:i21-7.
    12736227
  • Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW.A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.Clin Cancer Res. 2002 Oct;8(10):3075-81.
    12374674
  • Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.Bone Marrow Transplant. 2001 Sep;28(5):447-54.
    11593317
  • Joyce RM, Kraser CN, Tetrealt JC, Giallombardo N, McDermott D, Levine J, Umiel T, Regan M, Hurley D, Uhl L, Avigan D.Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.Eur J Haematol Suppl. 2001 Jul(64):56-62.
    11486404
  • Avigan D, Wu Z, Joyce R, Elias A, Richardson P, McDermott D, Levine J, Kennedy L, Giallombardo N, Hurley D, Gong J, Kufe D.Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer.Bone Marrow Transplant. 2000 Jul;26(2):169-76.
    10918427
  • McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.Clin Cancer Res. 2000 Jun;6(6):2201-8.
    10873069
  • Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB.Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.Clin Cancer Res. 2000 May;6(5):1678-92.
    10815886
  • McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB.A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.Clin Cancer Res. 1998 May;4(5):1203-13.
    9607578
  • Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB.Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.J Urol. 1997 Nov;158(5):1691-5.
    9334580
  • Murray HW, Hariprashad J, McDermott DF, Stoeckle MY.Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection.Infect Immun. 1996 Jan;64(1):161-6.
    8557335
  • Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD, Murray HW.Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis.Infect Immun. 1994 Mar;62(3):1058-63.
    8112840
  • Murray HW, Miralles GD, Stoeckle MY, McDermott DF.Role and effect of IL-2 in experimental visceral leishmaniasis.J Immunol. 1993 Jul 15;151(2):929-38.
    8335921
  • McDermott DF, Jaffe EA, Coleman M, Pasmantier MW.The effect of surgical debulking on the response of patients with ovarian carcinoma to chemotherapy.Am J Clin Oncol. 1988 Oct;11(5):520-3.
    3177252
  • McDermott DF, Galindo A, Sherman RL, Jaffe EA, Coleman M, Pasmantier MW.Inadequacy of predicted creatinine clearance as guide to chemotherapy.Cancer Treat Rep. 1987 Nov;71(11):1067-9.
    3677111